Neurona Therapeutics Inc.

Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Scion Life Sciences, an affiliate of the health care investment firm Petrichor, launched on 7 February with two friends and former Apple Tree Partners (ATP) colleagues – Scion co-founders and managing

“Biomedical innovation is at its golden age, and scientific innovation will continue to be strong,” declared Søren Møller , managing partner at Novo Seeds , the life science start-up financing arm o